In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Amfipen; Ampicin; Binotal; D-Amp; Marcillin; Penbritin; Penstabil; Principen; Pro-Ampi; Sinaplin; Taro-Ampicillin Trihydrate; Totacillin (GSK); Totapen; Vidopen
- INDICATIONS: Susceptible strains of gram-negative and gram-positive bacterial infections
- CLASS: Antibiotic, Antibiotic; beta-lactam, Antibiotic; penicillin, Antimicrobial
- HALF-LIFE: 1–1.5 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Allopurinol, Anticoagulants, Chloramphenicol, Cyclosporine, Demeclocycline, Doxycycline, Erythromycin, Imipenem/Cilastatin, Levodopa, Methotrexate, Minocycline, Oxytetracycline, Sulfonamides, Tetracycline
- See adverse reactions attributed to class:
Five to 10% of people taking ampicillin develop eruptions between the 5th and 14th day following initiation of therapy. Also, there is a 95% incidence of exanthematous eruptions in patients who are treated for infectious mononucleosis with ampicillin. The allergenicity of ampicillin appears to be enhanced by allopurinol or by hyperuricemia. Ampicillin is clearly the more allergenic of the two drugs when given alone.
Please login to view the rest of this drug profile.
Page last updated 01/27/2024
